Progressive Treatment Strategies for DLBCL Directed by NCCN

A medical expert examines first6, second-, and third-line systemic therapies for DLBCL in accordance with NCCN Guidelines.

Related Keywords

Phoenix , Arizona , United States , Catherine Thieblemont , Cleo Gordon , Novartis , Transcend , New England Journal , Clinical Oncology , Epcoritamab , B Cell Lymphoma , Dlbcl , Nccn , Nccn Guidelines , Chop , Chop Chemotherapy , Phoenix Clinical Trial , Gemcitabine , Rituxan , Transform Study ,